CMTA is funding four research projects targeting a fundamental barrier to CMT treatment: getting therapies past the biological defenses protecting peripheral nerves. The $523,000 CMTA-STAR investment supports complementary delivery approaches, including gene editing, RNA medicine, and nanoparticles, across multiple CMT subtypes.
CMTA Addresses the Critical Delivery Challenge Underlying CMT Treatment Development through Four Key Investments
CMTA announced $523,000 in funding for four research projects focused on solving one of the biggest challenges in CMT treatment development: delivering therapies to peripheral nerve cells. By investing in genome-editing transport, blood-nerve barrier crossing, Schwann cell targeting, and nanoparticle systems, CMTA is working to ensure treatments can reach the cells where they are needed.
MDA, CMTA Announce Grant for Collaborative Non-Viral Gene Therapy Research on CMT1X
CMTA and MDA announced a joint three-year study evaluating a nanoparticle delivery approach for CMTX1. The project will test nanoparticle-based delivery of a therapeutic gene to Schwann cells as a potential treatment strategy.
